Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-α
- 1 May 2006
- journal article
- review article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (4) , 371-380
- https://doi.org/10.1016/j.ejso.2006.01.015
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- TNF dose reduction in isolated limb perfusionEuropean Journal of Surgical Oncology, 2005
- One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit MetastasesAnnals of Surgery, 2004
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanomaEuropean Journal of Surgical Oncology, 2004
- Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan aloneEuropean Journal of Surgical Oncology, 2001
- Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastasesCancer, 1999
- A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limbEuropean Journal Of Cancer, 1996
- Isolated limb perfusion with TNFα and melphalan in a rat osteosarcoma model: a new anti-tumour approachEuropean Journal of Surgical Oncology, 1996
- High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancerEuropean Journal Of Cancer, 1995
- Regional therapy of melanomaEuropean Journal Of Cancer, 1993